LB Pharmaceuticals Inc
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-25.2M | $-63.1M |
| Depreciation & Amortization | $321.0K | $91.0K |
| Depreciation | — | — |
| Amortization | — | — |
| Stock-Based Compensation | $4.2M | $3.1M |
| Net Cash from Operating Activities | $-35.2M | $-53.1M |
| Investing Activities | ||
| Capital Expenditures | $52.0K | $769.0K |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-39.9M | $23.2M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $302.6M | $38.3M |
| Net Change in Cash | $227.5M | $8.5M |
| Free Cash Flow | $-35.3M | $-53.8M |